Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, marking a significant move in the PROTACs technology space.
Browsing: M&A and Licensing
News and insights on mergers, acquisitions, licensing deals, and strategic collaborations across the global pharma industry.
Johnson & Johnson acquires Halda Therapeutics for $3.05 billion, enhancing its cancer treatment pipeline.
Alkermes Avadel bid increases as the company aims to strengthen its position in the US market.
Pfizer Metsera deal finalizes at $10 billion, enhancing Pfizer’s pipeline and market position.
Alkermes bidding war with Lundbeck over a sleepiness drug could impact its market strategy and financial outlook.
Novo Nordisk acquires Akero Therapeutics for $5.2 billion, enhancing its MASH treatment pipeline.
Chiesi Arbor partnership focuses on advancing gene editing therapies for rare diseases, targeting primary hyperoxaluria type 1.
Pharma companies are seeking agreements with Trump following Pfizer’s deal, aiming to lower drug prices.
Algen AstraZeneca partnership aims to enhance AI-driven drug discovery, focusing on chronic inflammatory conditions for innovative solutions.
Galapagos cell therapy sale decision expected soon as company reviews limited proposals from financial investors.